S&P 500 Financials Sector SEC Filings — May 26, 2026

26-05-2026

ERock, Inc. filed Amendment No. 1 to its S-1 registration statement with the SEC on May 26, 2026, as an exhibits-only filing. The company, a Delaware corporation headquartered in Houston, Texas, is proceeding toward an initial public offering, with John Carrington serving as CEO. The filing includes various exhibits such as underwriting agreement forms, equity incentive plans, and lease agreements, but no new financial or operational data is provided in this amendment.

• · The filing is an exhibits-only amendment; no financial statements or business updates are included.
• · The company is an emerging growth company and a non-accelerated filer.
• · Director nominees include Charles Boynton, Dan Brouillette, Hans Kobler, Mark Petterson, Sameer Reddy, Tony Satterthwaite, and Lindsay Luger.
• · The company has multiple lease agreements with Vine Street Studios, LLC, Duke Realty Limited Partnership, and Prologis, L.P., with dates ranging from 2018 to 2026.
• · The registration number is 333-295965.

26-05-2026

Core AI Holdings, Inc. filed an Amendment No. 1 to its Annual Report on Form 20-F/A on May 26, 2026, primarily to update exhibits. The filing incorporates by reference various corporate documents, including articles of association, warrant forms, stock option plans, promissory notes, securities purchase agreements, and consulting agreements. No new financial results or operational metrics are disclosed in this filing.

• · The filing includes a new form of pre-funded warrant to purchase 588,236 shares at an exercise price of $0.00004 per share.
• · The filing incorporates by reference multiple prior securities purchase agreements, promissory notes, and consulting agreements from 2024.
• · The company's articles of association have been amended multiple times, with the latest alteration filed on October 29, 2024.

26-05-2026

Veritone, Inc. filed additional definitive proxy materials (DEFA14A) on May 26, 2026, to solicit votes in connection with its upcoming shareholder meeting. The filing provides supplemental soliciting materials under Rule 14a-12 and contains no new financial results or operational updates.

• · The filing is a definitive additional proxy solicitation material (DEFA14A), not preliminary or definitive proxy statement.
• · No fee was required for this filing.
• · The filing references Schedule 14A and Rule 14a-12 under the Securities Exchange Act of 1934.

26-05-2026

Octave Intelligence plc, a spin-off from Hexagon AB, announced the distribution of its shares to Hexagon shareholders and the commencement of trading on Nasdaq Stockholm (SDRs under 'OCTV SDB') and Nasdaq New York (class B ordinary shares under 'OCTV'), with the first day of regular-way trading on Nasdaq New York expected on May 28, 2026. The company also designated Ireland as its Home Member State for regulatory purposes. The filing highlights the successful separation from Hexagon and the dual listing, but notes forward-looking risks related to operating as an independent public company and market conditions.

• · Share distribution ratio: one class A ordinary share in Octave for every ten Series A shares held in Hexagon, and one class B ordinary share for every ten Series B shares held in Hexagon.
• · Record date for distribution: May 22, 2026.
• · SDRs trade on Nasdaq Stockholm under ticker 'OCTV SDB' with ISIN SE0028329433.
• · Class B ordinary shares trade on Nasdaq New York under ticker 'OCTV' with ISIN IE0003YHD8K8 and CUSIP G22845 104.
• · First day of regular-way trading on Nasdaq New York expected May 28, 2026.
• · SDR conversion to underlying class B ordinary shares is free of charge for the first six months from the first day of trading on Nasdaq Stockholm; thereafter a conversion fee applies.
• · Octave is an Irish company with registered office in Ireland and has chosen Ireland as its Home Member State.
• · Forward-looking statements caution about risks including separation from Hexagon, independent operations, market conditions, and competitive pricing.

26-05-2026

GameStop Corp. disclosed that on May 22, 2026, Chairman and CEO Ryan Cohen posted on X about a proposed acquisition of eBay Inc. at $125 per share in a cash-and-stock deal. GameStop already holds 25,000 eBay shares directly and has economic exposure to an additional 29,078,699 shares via put/call option pairs expiring February 23, 2028. The proposal is non-binding and subject to regulatory approvals, financing, and shareholder votes; eBay's board has not yet engaged.

• · The put/call option pairs expire on February 23, 2028, and are settleable in cash until the HSR Act Condition is satisfied; thereafter, settleable in cash or shares at the exercising party's option.
• · GameStop delivered a non-binding proposal to eBay's board on May 3, 2026.
• · The proposed consideration is a combination of cash and GameStop common stock.
• · GameStop has not had access to eBay's books and records.
• · The filing is deemed solicitation material under Rule 425 and Rule 14a-12.
• · GameStop's 2026 Annual Meeting of Stockholders is scheduled for July 7, 2026 at 10:00 a.m. CDT.

26-05-2026

AITX announced that its subsidiary RAD has added 12 more RIO Minis at a massive construction site, as per a press release issued on May 26, 2026. The filing is an 8-K furnishing the press release under Item 8.01, with no financial details or performance metrics provided.

• · The press release is titled 'AITX's RAD Adds 12 More RIO Minis at Massive Construction Site'.
• · The filing is dated May 26, 2026, and is furnished under Item 8.01.

26-05-2026

Cumberland Pharmaceuticals Inc. (CPIX) entered into an Asset Purchase Agreement on April 22, 2026, to sell its FDA-approved product assets (Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ) to an affiliate of Apotex Inc. for $100M in cash. The pro-forma financials show the company would have retained a significantly smaller revenue base of $168,850 for the three months ended March 31, 2026, down from $9.1M historically, while also showing a pro-forma net loss of $1.73M for that period. However, the company would have received a substantial cash infusion, with pro-forma cash and cash equivalents of $110.2M as of March 31, 2026, up from $11.0M historically, and will retain its earlier-stage ifetroban product candidates and majority-owned subsidiary Emerging Technologies, Inc.

• · The transaction is expected to close with a transition services agreement where Cumberland will provide services to Apotex for up to 12 months post-closing.
• · Pro-forma basic and diluted net loss per share for the three months ended March 31, 2026 is $(0.12), compared to a historical loss of $(0.22).
• · Pro-forma basic and diluted net loss per share for FY2025 is $(0.53), compared to a historical loss of $(0.19).
• · Pro-forma basic and diluted net loss per share for FY2024 is $(0.45), compared to a historical loss of $(0.46).
• · The company will retain $5.2M in revolving line of credit debt on a pro-forma basis.
• · The pro-forma balance sheet eliminates $12.7M in intangible assets and $914,000 in goodwill related to the sold assets.

26-05-2026

Elmet Group Co. amended its bylaws to change its fiscal year end from December 31 to a 4-4-5 fiscal calendar, effective January 1, 2026. Under the new calendar, the fiscal year ends on the Friday closest to December 31, with the first such year ending January 1, 2027. The change aims to better align accounting operations with quarterly reporting and improve comparability, though it may cause temporary incomparability for certain fiscal quarters.

• · The Board approved the fiscal year change on May 19, 2026.
• · The first fiscal year under the new calendar began January 1, 2026 and ends January 1, 2027.
• · Fiscal quarters ending April 3, 2026, July 3, 2026, and October 2, 2026 may not be fully comparable to prior year quarters due to different numbers of days.
• · Subsidiaries with a different fiscal year end will continue to be consolidated using financial statements within three months of the company's fiscal year end, with adjustments for material transactions.
• · The change does not affect previously issued financial statements or tax reporting.
• · The company is designated as an emerging growth company.

26-05-2026

Specificity, Inc. (SPTY) disclosed on May 22, 2026 that it will restate its 2025 annual financial statements due to errors from failing to review bank and credit card statements for accounts opened in mid-December 2025. The preliminary correction shows an understatement of expenses of $83,422, an understatement of revenues of $2,500, an understatement of liabilities of $121,122, an overstatement of additional paid-in capital of $40,000, and an understatement of cash of $202. The company believes the errors do not affect quarterly operating results in 2025 and is concurrently filing an amended 10-K/A and completing its delayed Q1 2026 10-Q.

• · The errors were identified on May 15, 2026.
• · The company delayed its Q1 2026 10-Q and filed a Form 12b-25.
• · The restatement amounts are subject to completion of CM3 Advisory review.
• · The company intends to file the amended 10-K/A and the Q1 2026 10-Q as soon as practical.

26-05-2026

Goldman Sachs Private Credit Corp. reported a NAV of approximately $9.3 billion as of April 30, 2026, with a fair value investment portfolio of $16.9 billion and fund leverage of 0.8x. The company sold 3,413,404 unregistered shares for $84,185,000 in May 2026, and declared an April distribution with annualized yields ranging from 8.2% to 9.0%. Total return based on NAV for Class I shares was 7.8% over one year, but Class S and D shares have limited track records (inception in 2026) with year-to-date returns of 1.0% and 1.3%, respectively.

• · Fund leverage was 0.8x as of April 30, 2026, calculated using average daily borrowings divided by average net assets.
• · The April 2026 distribution is payable on or about May 28, 2026 to stockholders of record as of April 30, 2026.
• · Class I shares have been outstanding since April 6, 2023; Class S shares since February 1, 2026; Class D shares since March 1, 2026.
• · NAV per share for all three classes was $24.66 as of April 30, 2026.
• · No Class D shares were sold in the May 2026 offering.

26-05-2026

Calavo Growers (CVGW) and Mission Produce announced receipt of antitrust clearance from Mexico's COFECE for Mission Produce's pending acquisition of Calavo. Subject to all conditions being satisfied, the merger is currently expected to close on May 28, 2026.

• · Antitrust clearance was obtained from Mexico's Federal Economic Competition Commission (COFECE).
• · The merger is expected to be consummated on May 28, 2026.
• · A joint proxy statement/prospectus was mailed to shareholders on or about March 25, 2026.
• · The registration statement on Form S-4 (File Number 333-294128) has become effective.

26-05-2026

Odyssey Health, Inc. (ODYY) entered into Amendment No. 12 to its Convertible Promissory Note with LGH Investments, LLC, extending the maturity date from an unspecified prior date to September 30, 2026. The original note was dated April 5, 2021, with a loan amount of $1,050,000. This marks the twelfth amendment to the note, indicating repeated extensions and potential ongoing liquidity challenges.

• · The original Convertible Promissory Note was issued on April 5, 2021, for $1,050,000.
• · The maturity date has been extended to September 30, 2026, through this amendment.
• · This is the twelfth amendment to the note, suggesting a pattern of repeated extensions.
• · The amendment was effective as of April 30, 2026.

26-05-2026

Encore Capital Group issued $750.0 million in 6.625% senior secured notes due 2032, with interest payable semi-annually starting December 1, 2026. The notes are secured by substantially all assets of the company and its guarantors, and are fully guaranteed by material subsidiaries. The filing does not disclose any negative or flat performance metrics, as it is a debt issuance event.

• · Interest on the notes is payable semi-annually on June 1 and December 1, beginning December 1, 2026.
• · The notes mature on June 1, 2032, unless earlier repurchased or redeemed.
• · The indenture includes subsidiary guarantors and is secured by substantially all assets of the company and guarantors.

26-05-2026

TriCo Bancshares (TCBK) announced a quarterly cash dividend of $0.36 per share, payable on June 26, 2026 to shareholders of record as of June 5, 2026. The dividend was declared by the Board of Directors on May 21, 2026. No comparative prior dividend or performance metrics were provided in the filing.

• · Dividend record date: June 5, 2026
• · Dividend payable date: June 26, 2026
• · Filing date: May 26, 2026; event date: May 21, 2026

26-05-2026

Xcel Brands, Inc. filed an 8-K on May 26, 2026, reporting additional share issuances under its existing common stock purchase agreement with White Lion Capital LLC. On May 20 and May 22, 2026, the Company sold a total of 7,500 shares for aggregate proceeds of $15,650, with purchase prices of $4,950 (2,500 shares at $1.98 average) and $10,700 (5,000 shares at $2.14 average). As of May 22, 2026, total accumulated proceeds under the agreement were $15,650, representing only a tiny fraction of the $15.0 million commitment, indicating very limited utilization of the facility.

• · The Purchase Agreement was entered into on January 21, 2026 (Execution Date).
• · The Purchase Agreement includes a registration rights agreement with the Investor.
• · The average of the 3 lowest trades on May 20, 2026 was $1.98 per share; on May 22, 2026 it was $2.14 per share.
• · The purchase price per share is based on the average of the 3 lowest trades on the purchase date.
• · The Company's common stock trades on the Nasdaq Capital Market under symbol XELB.

26-05-2026

Pinterest held its 2026 annual meeting on May 21, 2026, where all four Class I director nominees (Chip Bergh, Gokul Rajaram, Emily Reuter, Marc Steinberg) were elected, and shareholders approved executive compensation on a non-binding advisory basis. The company also ratified Ernst & Young LLP as its independent auditor for fiscal 2026 and decided to hold future advisory votes on executive compensation annually. All proposals passed with strong majority support, though Chip Bergh received the lowest 'for' votes among nominees (1,795,684,711) and the highest 'against' votes (152,462,358), indicating some shareholder dissent.

• · Record date for voting was March 27, 2026.
• · Class A common stock holders had 1 vote per share; Class B holders had 20 votes per share.
• · All director nominees were elected to serve until the 2029 annual meeting.
• · Chip Bergh received 1,795,684,711 for, 152,462,358 against, 346,546 abstain, and 47,220,520 broker non-votes.
• · Gokul Rajaram received 1,906,257,236 for, 41,887,444 against, 348,935 abstain, and 47,220,520 broker non-votes.
• · Emily Reuter received 1,945,691,087 for, 2,451,265 against, 351,263 abstain, and 47,220,520 broker non-votes.
• · Marc Steinberg received 1,939,563,390 for, 8,587,510 against, 342,715 abstain, and 47,220,520 broker non-votes.
• · Executive compensation (say-on-pay) received 1,872,585,095 for, 75,176,625 against, 731,895 abstain, and 47,220,520 broker non-votes.
• · Frequency vote: 1,940,750,588 for one year, 136,194 for two years, 7,018,838 for three years, 587,995 abstain.
• · Ratification of Ernst & Young: 1,980,724,813 for, 14,669,424 against, 319,898 abstain.

26-05-2026

Nuvve Holding Corp. received a Nasdaq notice on May 22, 2026, for failing to file its Q1 2026 Form 10-Q on time, violating Listing Rule 5250(c)(1). This adds a second delisting basis to an existing proceeding for the stock price falling below $1.00. The company has until May 29, 2026, to request a stay of suspension and intends to take all reasonable measures to regain compliance and remain listed.

• · The company is already before the Nasdaq Hearings Panel due to its common stock closing price falling below $1.00 per share for 30 consecutive trading days under Listing Rule 5550(a)(2).
• · The new delisting basis stems from failure to file the Quarterly Report on Form 10-Q for the period ended March 31, 2026.
• · If the company regains compliance before a scheduled hearing, the hearing may be mooted out.
• · The company issued a press release on May 22, 2026, regarding the notice, furnished as Exhibit 99.1.

26-05-2026

SharonAI Holdings appointed Mr. Andrew Penn AO as non-executive Chairman of the board, effective May 22, 2026. Mr. Penn brings extensive experience from Telstra, AXA Asia Pacific, and McKinsey, and is expected to guide the company's strategic growth. No financial figures or period-over-period comparisons were provided in this filing.

• · Mr. Penn was formerly CEO of Telstra (2015-2022) and CEO of AXA Asia Pacific Holdings (2006-2011).
• · He is currently a non-executive director and Chair of the Audit and Risk Committee of Coles Group, Chair of Visit Victoria, and a Senior Adviser with McKinsey & Company.
• · Mr. Penn was named an Officer of the Order of Australia (AO) in the 2023 Australia Day honours.
• · Sharon AI primarily uses its Investor Relations page for material disclosures and also uses X and LinkedIn for additional dissemination.

26-05-2026

Golub Capital Private Income Fund S reported a NAV per share of $24.17 as of April 30, 2026, with a portfolio of 142 companies valued at approximately $248 million. The fund sold 11,570 unregistered common shares for $279,650 and declared a May 2026 net distribution of $0.1493 per share. The portfolio is heavily weighted toward first lien senior secured debt (98%) and floating-rate investments (100%), with a debt-to-equity leverage ratio of 1.31x.

• · The May 2026 net distribution per common share is $0.1493, payable to shareholders of record as of May 31, 2026, paid on or around June 29, 2026.
• · The gross distribution per share is $0.1667, with a shareholder servicing/distribution fee of $0.0174.
• · Top industry exposures: Software 25%, Insurance 10%, Healthcare Providers & Services 6%, Hotels, Restaurants & Leisure 6%, Healthcare Equipment & Supplies 5%, Automobiles 5%, Commercial Services & Supplies 5%, Containers & Packaging 4%, Healthcare Technology 4%, Professional Services 4%.
• · Three debt investments (less than 1% of portfolio) have fixed interest rates.
• · No underwriting discounts or commissions were paid in connection with the share sale; selling agents may charge up to 3.5% of NAV in fees.

26-05-2026

Golub Capital Private Income Fund I disclosed its April 30, 2026 portfolio and NAV metrics in an 8-K filing. The fund reported a NAV per share of $24.22, total portfolio fair value of approximately $433 million across 142 companies, and a debt-to-equity leverage ratio of 1.24x. The fund also announced a May 2026 regular distribution of $0.1667 per common share, payable on June 29, 2026.

• · The fund's GAAP debt-to-equity ratio, net of cash, was 1.19x as of April 30, 2026.
• · Three debt investments representing less than 1% of the portfolio had fixed interest rates.
• · Top industry exposure was Software at 23% of fair value, followed by Insurance (10%) and Commercial Services & Supplies (7%).
• · The May 2026 regular distribution of $0.1667 per share is payable to shareholders of record as of May 31, 2026.
• · No underwriting discounts or commissions were paid in connection with the unregistered share sale.

26-05-2026

Global Interactive Technologies, Inc. (GITS) filed its 10-K annual report for the fiscal year ended May 26, 2026, detailing its monetization model centered on Vote & Boost sales, premium subscriptions, and scalable advertising. The company continues to incur recurring losses, has a working capital deficiency, and its auditors have expressed substantial doubt about its ability to continue as a going concern, requiring significant additional capital. Despite these risks, GITS is expanding its IP portfolio (including music distribution and The Nut Job 3) and leveraging a user-centric economy with 50% of daily net advertising profits distributed as FP to users.

• · The company's auditors have stated that substantial doubt exists about its ability to continue as a going concern.
• · The company has incurred recurring losses from operations and has a working capital deficiency.
• · The company requires significant additional capital to continue as a going concern.
• · The value of FP is maintained at a fixed ratio of 1 FP to 100 Korean Won.
• · The company expanded its IP portfolio in 2025 to include distribution of music for K-pop artists and international animation projects such as The Nut Job 3.
• · The real-time translation engine currently supports 17 languages.
• · Communications are protected through end-to-end encryption (E2EE).
• · New communities are automatically activated when user requests for a specific topic reach a strategic threshold.
• · The company plans to produce 2-minute short-form cultural content for distribution on Faning and third-party social media networks.

26-05-2026

Mountain Lake Acquisition Corp. II (MLAC II) disclosed that the exclusivity provisions of its non-binding letter of intent with Terra Quantum AG have expired, allowing MLAC II to pursue discussions with other potential business combination targets. While discussions with Terra Quantum may continue, the company is now free to explore alternative transactions, introducing uncertainty regarding the original deal.

• · The non-binding letter of intent with Terra Quantum was entered into in April 2026.
• · MLAC II is a blank check company (SPAC) incorporated in the Cayman Islands, with units, Class A ordinary shares, and warrants listed on Nasdaq under symbols MLAAU, MLAA, and MLAAW respectively.
• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.

26-05-2026

Editas Medicine presented preclinical data for EDIT-401 at the 94th EAS Congress, showing robust reductions in LDL-C, Lp(a), and ApoB in non-human primates. A single dose achieved 90% or greater mean reduction in LDL-C with durability through six months. The company plans to submit a CTN in Australia in mid-2026 and initiate a first-in-human trial in HeFH patients later in 2026, with early proof-of-concept data expected by end of 2026. However, higher doses (3 mg/kg and 6 mg/kg) showed liver enzyme increases and adverse observations, and functional liver editing rates were low at 12.4%.

• · EDIT-401 achieved rapid, dose-dependent mean reduction of approximately 90% in Lp(a) and ApoB.
• · Reductions in LDL-C, Lp(a), and ApoB were highly correlated, supporting a unified mechanism via LDL receptor upregulation.
• · Interim GLP toxicology results showed EDIT-401 was well-tolerated at 1.5 mg/kg with no adverse clinical observations, no notable liver enzyme elevations, and no liver histopathology findings.
• · Low functional liver editing rate of 12.4% at 1.5 mg/kg; low editing detected in adrenal gland, spleen, and ovary; no significant editing in other extrahepatic tissues.
• · At 3 mg/kg, minimal to marked liver enzyme increases and non-adverse liver findings; at 6 mg/kg, adverse clinical observations in one NHP.
• · Company received pre-IND feedback from FDA on nonclinical package, CMC plans, and study design.
• · Part 1 of Phase 1/2 trial expected to enroll ~18 HeFH patients in three dosing arms; Part 2 is a randomized, placebo-controlled expansion with ~28 patients.
• · Topline data from Part 1 expected in 2027.

26-05-2026

News Corp filed an 8-K to disclose daily ASX disclosures related to its $1B stock repurchase program. The company is authorized to repurchase up to $1B in aggregate of Class A and Class B common stock. The filing includes forward-looking statements regarding the intent to repurchase shares from time to time.

• · The repurchase program covers both Class A common stock (NWSA) and Class B common stock (NWS).
• · Exhibits 99.1 and 99.2 contain the ASX disclosures for specific dates.
• · The company is required to provide daily ASX disclosure of repurchase transactions under ASX rules.

26-05-2026

NOG announced a strategic entry into Canada with a CA$350 million (~US$259 million) acquisition of a 25% non-operated stake in light oil Duvernay Shale assets from Parallax Energy Operating Inc., with ~CA$113 million (~US$83.5 million) paid in NOG common stock and the remainder in cash. The assets include ~4,000 Boe/d of production (80% light oil) and 75,000 net acres with ~20 years of inventory and breakevens below $50 WTI. The transaction is expected to be leverage neutral and accretive to key valuation metrics, but NOG also updated its 2026 guidance with slightly higher production and oil output while keeping capital expenditures unchanged at $850–$900 million.

• · The effective date for the transaction is April 1, 2026, with closing expected late in Q2 2026.
• · NOG expects to incur up to $40–$45 million in capital expenditures on the assets post-closing in 2026, and $45–$50 million in 2027.
• · Operating costs on the acquired assets are expected to be less than $7.50 per Boe/d, below NOG's corporate average.
• · NOG intends to enter into derivatives transactions to hedge currency fluctuations related to operating costs on a multi-year basis.
• · NOG may repurchase a portion of the stock consideration in the open market depending on market conditions.
• · The contingent consideration of CA$25 million (~US$18.5 million) is payable in Q1 2028 if certain average oil prices are achieved through end of 2027.
• · Gas realization as a % of Henry Hub/MCF was revised downward from 70%–75% to 70.0%–72.5%, indicating slightly weaker gas pricing expectations.
• · Production taxes as a % of oil & gas sales were revised upward from 7%–8% to 7.5%–8.0%.

26-05-2026

Hycroft Mining Holding Corporation announced via press release on May 26, 2026, that its Class A common stock (HYMC) will be added to the broad-market Russell 3000® Index effective June 29, 2026. This inclusion may enhance the company's visibility and liquidity among institutional investors. No financial results or negative developments were disclosed in this filing.

• · The press release is attached as Exhibit 99.1 to the Form 8-K.
• · The filing is under Item 7.01 Regulation FD Disclosure and is not deemed filed for Exchange Act purposes.
• · The company's Class A common stock trades under the symbol HYMC on Nasdaq.
• · The effective date for the index addition is June 29, 2026.

26-05-2026

CSW Industrials reported net revenues of $1,082.5M for fiscal year 2026, a 23.3% increase from $878.3M in 2025, driven by strong growth in its largest segment. However, operating income declined 7.0% to $168.5M from $181.2M, and operating margin contracted to 15.6% from 20.6%, reflecting higher SG&A expenses and a loss in one segment. Net cash from operations also fell 11.1% to $149.7M, while investing activities surged due to a $1.04B cash outflow.

• · Segment A (largest) revenues grew 31.3% YoY to $810.3M, but its operating margin fell to 21.7% from 26.9%.
• · Segment B revenues increased 8.4% to $160.1M, yet operating margin declined to 13.8% from 15.4%.
• · Segment C revenues declined 1.0% to $119.9M and swung to an operating loss of $1.2M from a profit of $19.2M.
• · SG&A expenses rose 34.5% to $285.1M, outpacing revenue growth, and as a percentage of revenue increased to 26.3% from 24.1%.
• · Net cash used in investing activities surged to $1.04B from $102.2M, likely reflecting a major acquisition or capital expenditure.
• · Financing activities provided $701.5M in cash, compared to $138.0M in 2025, indicating significant debt or equity issuance.

26-05-2026

TransCode Therapeutics disclosed it received a Nasdaq deficiency letter on May 19, 2026, for failing to meet the minimum stockholders' equity requirement of $2.5 million, reporting only $1,251,427 in equity as of March 31, 2026. The company has until July 3, 2026, to submit a compliance plan, which hinges on stockholder approval to convert Series A and Series B Preferred Stock into common stock. Failure to regain compliance could lead to delisting, materially impacting the company's operations and share value.

• · The company's common stock trades on the Nasdaq Capital Market under the symbol RNAZ.
• · If stockholder approval for conversion of Series A Preferred Stock is not obtained by December 31, 2026, holders can elect redemption at estimated fair value.
• · As of March 31, 2026, Series A Preferred Stock was classified as temporary equity due to the redemption feature.
• · The company also plans to seek approval for conversion of Series B Non-Voting Convertible Preferred Stock and a 'change of control' under Nasdaq rules.
• · A preliminary proxy for the stockholder meeting was filed on May 8, 2026.

26-05-2026

Ares Capital Corporation (ARCC) entered into a Seventeenth Amended and Restated Senior Secured Credit Agreement dated May 21, 2026, increasing its revolving credit facility to $5.481 billion from the prior facility. The agreement involves a syndicate of major banks led by JPMorgan Chase as administrative agent and includes provisions for multi-currency borrowings, letters of credit, and swingline loans. The filing does not disclose any negative financial performance metrics, as it is a financing agreement update rather than an earnings report.

• · The agreement amends and restates the existing credit facility originally dated December 28, 2005, as last amended on April 15, 2025.
• · The facility includes multicurrency borrowing options in CAD, GBP, EUR, and potentially other foreign currencies.
• · Non-extending lenders identified include Bank of Communications (2024), Comerica Bank (2025), and Société Générale, Land Bank of Taiwan, First Commercial Bank (2026).
• · The agreement includes provisions for borrowing base calculations, financial covenants, and events of default.
• · The facility is secured and includes representations, warranties, and affirmative/negative covenants typical for such agreements.

26-05-2026

Ares Strategic Income Fund entered into a Third Amended and Restated Senior Secured Credit Agreement dated May 21, 2026 with JPMorgan Chase Bank as Administrative Agent and seven other syndication agents, securing a $4.1 billion credit facility that amends and restates the prior $4.1 billion facility dated April 15, 2025. The facility is a senior secured revolving credit line that refinances existing commitments with largely the same bank syndicate and administrative agent, demonstrating continued strong lender support and access to institutional capital markets.

• · The facility size remains at $4.1 billion, unchanged from the prior Second Amended and Restated facility dated April 15, 2025, indicating stable credit capacity rather than an expansion.
• · The agreement includes multicurrency borrowing capabilities in AUD, CAD, CHF, EUR, GBP, SEK, and Yen, providing significant foreign currency flexibility.
• · The administration of the facility includes JPMorgan Chase as Administrative Agent and a syndicate of seven additional major banks as bookrunners and lead arrangers.
• · Interest rate options include Alternate Base Rate (ABR), Adjusted Term SOFR Rate, Adjusted EURIBOR Rate, Adjusted TIBOR Rate, Adjusted Daily Simple RFR (Sterling, CHF, USD, CAD), and Adjusted Term CORRA Rate, with floors applied to each.
• · The Borrower's outstanding unsecured notes (2028-2032 maturities) remain in place, totaling $4.9B in unsecured debt across eight tranches.

26-05-2026

Champion Homes reported mixed fiscal Q4 2026 results: net sales grew 4.6% to $621.3M and adjusted EBITDA rose 6.3% to $55.9M, but GAAP net income declined 18.4% to $29.7M due to acquisition-related charges and product liability true-ups. Full-year net sales increased 7.3% to $2.7B and adjusted net income rose 6.2% to $217.4M, while U.S. homes sold in Q4 fell 0.6% to 5,908 units and backlog decreased 8.0% year-over-year. The company ended the quarter with $638.3M in cash and repurchased $50M in stock during Q4.

• · Q4 fiscal 2026 adjusted gross profit margin was 25.7%, flat compared to prior-year period.
• · Full year fiscal 2026 adjusted gross profit margin was 26.6% vs 26.7% in fiscal 2025, a slight decline.
• · Q4 fiscal 2026 adjusted EBITDA margin increased slightly to 9.0% from 8.9% in prior-year period.
• · Full year fiscal 2026 adjusted EBITDA margin increased slightly to 11.6% from 11.5% in fiscal 2025.
• · Q4 fiscal 2026 EPS was $0.53; adjusted EPS was $0.68.
• · Full year fiscal 2026 EPS was $3.66; adjusted EPS was $3.85, up 9.4% YoY.
• · Canadian homes sold in Q4 increased to 243 from 230 in prior-year period.
• · The company acquired Iseman Homes in May 2025.
• · Board refreshed share repurchase authorization to $150 million in May 2026.
• · Conference call scheduled for May 26, 2026 at 8:00 AM Eastern Time.

26-05-2026

Quantinuum Inc. filed Amendment No. 1 to its S-1 registration statement for an initial public offering of 21,052,632 shares of Class A common stock, with an expected price range of $45.00 to $50.00 per share. The company will list on Nasdaq under the symbol 'QNT'. Post-IPO, Quantinuum Inc. will hold a 10.2% economic interest in Quantinuum Holdings, while continuing unitholders will hold 89.8%. The company is an emerging growth company and has elected reduced reporting requirements.

• · Quantinuum Inc. will be a holding company with sole asset being 10.2% of Common Units of Quantinuum Holdings.
• · Class B common stock has no economic rights or dividend rights.
• · The company has elected to be an emerging growth company, reducing public company reporting requirements.
• · Underwriters have a 30-day option to purchase up to an additional 3,157,894 shares.
• · Up to 5% of shares are reserved for sale to directors, officers, employees, and business associates.

26-05-2026

Wheels Up Experience Inc. announced that lead strategic investor Delta Air Lines has extended its lock-up restriction on all shares issued under the Investment and Investor Rights Agreement for an additional year through May 22, 2027. This extension covers more than 35% of the company's total outstanding shares as of May 22, 2026, and follows Delta's recent commitment for a $100 million term loan, signaling continued confidence in Wheels Up's transformation strategy.

• · Lock-up extension runs through May 22, 2027.
• · Delta's $100 million term loan was first announced on May 11, 2026.
• · Wheels Up provides on-demand private aviation and cargo services to individuals and government organizations.

26-05-2026

AutoZone reported Q3 FY2026 net sales of $4.8 billion, up 8.4% YoY, with domestic same store sales increasing 4.1% and total company same store sales up 3.9% (constant currency). Diluted EPS rose to $38.07 from $35.36 a year ago. However, gross margin declined 57 basis points to 52.2% due to a 77 bps non-cash LIFO impact, and international same store sales in constant currency grew only 1.6%, remaining challenged in Mexico and Brazil. Adjusted after-tax ROIC fell sharply to 36.3% from 43.5% a year ago.

• · Operating expenses as a percentage of sales improved to 33.1% from 33.3% YoY.
• · Net inventory per store was negative $107 thousand, compared to negative $142 thousand last year and negative $105 thousand last quarter.
• · Cash flow from operations for the 12-week period was $847.4 million, up from $769.0 million a year ago.
• · Capital spending in Q3 was $391.7 million, up from $345.9 million last year.
• · The company opened 57 new stores in the U.S., 20 in Mexico, and 5 in Brazil during the quarter.
• · Adjusted debt to EBITDAR remained flat at 2.5x.
• · Year-to-date net income declined to $1.64 billion from $1.66 billion in the prior year period.
• · International same store sales in constant currency for the 36-week period were 2.6%, below the 4.0% total company rate.

26-05-2026

Amerant Bancorp Inc. filed an 8-K on May 26, 2026, disclosing an investor presentation (Exhibit 99.1) to be used with existing and prospective investors. The filing is a Regulation FD disclosure and does not contain any financial results or material operational updates.

• · The presentation is attached as Exhibit 99.1 and incorporated by reference.
• · The information is furnished under Item 7.01 and not deemed filed for Section 18 liability purposes.
• · The filing includes a cover page interactive data file (Inline XBRL).

26-05-2026

Cartesian Therapeutics secured up to $150 million in non-dilutive financing from K2 HealthVentures, with an initial $50 million tranche funded, extending cash runway into 2028. The company expects topline data from the Phase 3 AURORA trial of Descartes-08 in myasthenia gravis in Q1 2027, with a BLA filing planned for mid-2027. However, Chief Medical Officer Miloš Miljković is stepping down for personal reasons, though the company expects continued support from Head of R&D Peter Traber.

• · Descartes-08 is an autologous anti-BCMA mRNA CAR-T designed for outpatient administration without preconditioning chemotherapy.
• · Phase 3 AURORA trial is randomized, double-blind, placebo-controlled with 1:1 randomization, six once-weekly outpatient infusions, and primary endpoint of proportion of patients with ≥3-point MG-ADL improvement at Month 4.
• · Phase 2 TRITON trial in myositis (dermatomyositis and antisynthetase syndrome) initiated April 2026; data from a subset expected in 1H27 to determine path to pivotal trial.
• · Phase 1/2 HELIOS pediatric trial in JDM initiated January 2026; FDA granted Rare Pediatric Disease Designation for Descartes-08 in JDM.
• · Morgan Stanley served as sole structuring agent for the credit facility.
• · Second tranche ($25M) requires achievement of specified clinical and financing milestones; third tranche ($25M) requires approval and sales milestones.

26-05-2026

Olema Pharmaceuticals entered into a clinical trial collaboration and supply agreement with Bayer to evaluate its novel KAT6 inhibitor, OP-3136, in combination with Bayer's NUBEQA (darolutamide) in a Phase 1b/2 study for metastatic castration-resistant prostate cancer (mCRPC). The study, expected to initiate in H2 2026, will enroll approximately 36 patients, with Bayer supplying darolutamide and Olema leading the study. The agreement is the first clinical collaboration for OP-3136, and Olema retains full global commercial and marketing rights to the compound.

• · The Phase 1b/2 study will evaluate safety, tolerability, and preliminary anti-tumor activity.
• · Bayer will supply darolutamide; Olema will lead the conduct of the study.
• · Clinical data and inventions related to the combined use will be jointly owned.
• · Olema maintains full global commercial and marketing rights to OP-3136.
• · This is the first clinical collaboration for OP-3136.

26-05-2026

Applied Aerospace & Defense, Inc. filed Amendment No. 1 to its S-1 registration statement for an initial public offering of 32,500,000 shares of common stock, with an estimated price range of $18.00 to $21.00 per share. The company will list on the NYSE under symbol 'AADX'. Post-IPO, affiliates of Greenbriar Equity Group will own approximately 81.0% of the common stock, making it a 'controlled company'. The company qualifies as an 'emerging growth company' and has elected reduced public company reporting requirements.

• · The company was originally formed as GB Eagle Topco, Inc. on October 7, 2022 and changed its name to Applied Aerospace & Defense, Inc. on November 14, 2025.
• · On November 14, 2025, AA&D Holdings, LP completed a merger with Rotor Topco, LP, combining the businesses of Applied Aerospace Structures Corporation and PCX Aerostructures, LLC.
• · The combination was accounted for as a common control transaction under common control of Greenbriar Equity Fund V, L.P.
• · The company has applied to list on the NYSE under the symbol 'AADX'.
• · The underwriters have a 30-day option to purchase up to an additional 4,875,000 shares.
• · Up to 1,625,000 shares (5.0% of the offering) are reserved for a directed share program for directors, officers, employees, and others.
• · The company is an 'emerging growth company' and has elected to use reduced public company reporting requirements.
• · Post-IPO, the company will be a 'controlled company' under NYSE rules due to Greenbriar's ownership.

26-05-2026

D-Wave Quantum Inc. announced on May 26, 2026 that its subsidiary Quantum Circuits, LLC received second year funding for the SQFab project from NORDTECH, a U.S. Department of War initiative. The award underscores the role of quantum computing in microelectronics innovation. No financial details were disclosed.

• · The SQFab project is one of four innovative programs selected by the U.S. Department of War through NORDTECH.
• · NORDTECH is one of eight hubs composing the U.S. Microelectronics Commons program.
• · The award is for second year funding, indicating continuation of a multi-year project.

26-05-2026

Outlook Therapeutics announced that the FDA granted its appeal following the Formal Dispute Resolution process, concluding that substantial evidence of effectiveness has been established for LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration (nAMD). The FDA directed the Division of Ophthalmology and the Office of Specialty Medicine to work with the Company on final labeling, and the Company expects to resubmit the BLA as a Class 1 resubmission in June 2026. This positive regulatory development follows the December 30, 2025 Complete Response Letter and represents a significant milestone for the Company.

• · The FDA's appeal decision was based on the Formal Dispute Resolution process with the Office of New Drugs.
• · The prior Complete Response Letter was issued on December 30, 2025.
• · The BLA resubmission is expected in June 2026 as a Class 1 resubmission.
• · The treatment is for neovascular age-related macular degeneration (nAMD).

26-05-2026

Passage Bio, Inc. held its 2026 Annual Meeting on May 19, 2026, where stockholders elected two Class III directors (Athena Countouriotis, M.D. and Sandip Kapadia) for three-year terms, ratified KPMG LLP as independent auditor for fiscal 2026, and approved on a non-binding advisory basis the compensation of named executive officers and a frequency of every year for future advisory votes on such compensation. All proposals were adopted, with the auditor ratification receiving the strongest support (2,083,031 shares for, 41,539 against).

• · The annual meeting was held on May 19, 2026, and the 8-K was filed on May 26, 2026.
• · Broker non-votes totaled 637,397 shares for director elections and the advisory compensation votes.
• · The auditor ratification had no broker non-votes, indicating it was a routine matter.
• · The board adopted a policy to hold advisory votes on executive compensation every year until the next required frequency vote.

26-05-2026

Ryan Specialty Holdings, Inc. announced on May 26, 2026 that its Board of Directors approved a $300 million increase to its share repurchase program, bringing the total authorization to $600 million. As of May 22, 2026, after accounting for recent repurchases in Q2 2026, $300 million remains available under the program. The company may repurchase shares through open market, private transactions, or Rule 10b5-1 plans, subject to market conditions and liquidity.

• · The share repurchase program increase was approved by the Board of Directors on May 26, 2026.
• · Repurchases may be executed via open market, privately negotiated transactions, Rule 10b5-1 trading plans, or accelerated share repurchases.
• · The company is not obligated to purchase any shares and may suspend or discontinue the program at any time without notice.
• · The press release is attached as Exhibit 99.1 and incorporated by reference.

26-05-2026

At Thermo Fisher Scientific's 2026 Annual Meeting held on May 20, 2026, shareholders elected all 11 director nominees and ratified the appointment of PricewaterhouseCoopers LLP as auditor for fiscal year 2026. However, a non-binding advisory proposal on executive compensation (say-on-pay) was not approved, with 214.5 million votes against versus 99.9 million in favor.

• · All 11 director nominees were elected with votes ranging from 281.8 million (Dion J. Weisler) to 314.4 million (Debora L. Spar) in favor.
• · The ratification of PricewaterhouseCoopers LLP as independent auditor passed with 296.9 million votes for, 36.1 million against, and 1.0 million abstentions.
• · The say-on-pay proposal received 214.5 million votes against (68.2% of votes cast), indicating significant shareholder dissatisfaction with executive compensation.

26-05-2026

Camping World Holdings held its Annual Meeting on May 21, 2026, with strong shareholder turnout of 88.6% (129.96M of 146.67M eligible votes). All three Class I director nominees were elected and both Proposals 2 (ratification of Deloitte as auditor) and 3 (advisory say-on-pay) were approved. While Proposal 2 passed overwhelmingly (99.8% FOR), Proposal 3 saw notable dissent with approximately 6.1M votes AGAINST representing 5.0% of votes cast (excluding broker non-votes), indicating modest shareholder concerns around executive compensation.

• · Mary J. George received 116,771,893 FOR votes (96.8% of votes cast excluding broker non-votes) vs 3,815,358 WITHHELD.
• · K. Dillon Schickli received 112,196,986 FOR votes (93.0% of votes cast excluding broker non-votes) vs 8,390,265 WITHHELD, the lowest support among the three nominees.
• · Matthew D. Wagner received 120,111,420 FOR votes (99.6% of votes cast excluding broker non-votes) vs 475,831 WITHHELD, the highest support.
• · The meeting record date was March 27, 2026; the Proxy Statement was filed on April 9, 2026.
• · All voting results were consistent with Board recommendations.

26-05-2026

Silicon Laboratories Inc. (SLAB) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its pending merger with Texas Instruments Incorporated expired on May 22, 2026, satisfying one condition to closing. The merger, under which Silicon Labs will become a wholly owned subsidiary of Texas Instruments, remains subject to other customary conditions, including receipt of certain other regulatory approvals. The filing does not provide any financial results or period-over-period comparisons.

• · The merger agreement was entered into on February 4, 2026.
• · The HSR Act waiting period expired at 11:59 p.m. Eastern Time on May 22, 2026.
• · The closing remains subject to other customary conditions, including receipt of certain other regulatory approvals.
• · The filing includes forward-looking statements and risk factors related to the merger.

26-05-2026

Emerald Holding, Inc. held its Annual Meeting on May 21, 2026, with a quorum of approximately 194.2 million shares present. Stockholders approved the re-election of three Class III directors, ratified PricewaterhouseCoopers LLP as the independent auditor for 2026, and approved non-binding advisory votes on executive compensation and the frequency of future advisory votes (choosing every three years). All proposals passed with strong support, though director Emmanuelle Skala received the highest number of withheld votes (3.2 million) among the nominees.

• · Proposal 1: Michael Alicea received 188,985,694 votes for and 984,809 withheld; David Levin received 189,840,037 for and 130,466 withheld; Emmanuelle Skala received 186,817,301 for and 3,153,202 withheld.
• · Proposal 2: Ratification of PwC passed with 194,198,308 for, 3,635 against, and 20,779 abstentions.
• · Proposal 3: Advisory vote on executive compensation passed with 189,521,520 for, 437,532 against, and 11,451 abstentions.
• · Proposal 4: Frequency of future advisory votes: 184,796,707 voted for every three years, 8,322 for two years, 5,154,137 for one year, and 11,337 abstentions.